Roche comes out against clearing takeover of drug manufacturer Catalent…
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings buyout…
Catalent to sell New Jersey facility…
Ardena acquires Catalents Somerset, NJ facility, expanding its US presence and boosting advanced oral drug product manufacturing capabilities.…
Catalent delays filing of annual report…
Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent…
…
Catalents (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical…
The Global Dermal Toxicity Testing Market Size was Valued at USD 2.27 Billion in 2023 and the Worldwide Dermal Toxicity…
Catalent exec sells over $76k in company stock…
Catalents (CTLT) new tie-up to support the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving…
Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.…
Robbins LLP is investigating the acquisition of Catalent, Inc. (CTLT) by Novo Holdings to determine if it is in the…
Ares Management Corp. and Blue Owl Capital Inc. are leading a group of private credit lenders providing $4.8 billion of…
Catalent executive sells $21,749 in company stock…
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
Catalent (CTLT) reports lower revenues in Biologics segments in its second-quarter fiscal 2024, resulting in overall soft performance.…
The pharmaceutical industry is a major player in the life science sector, responsible for developing and manufacturing the majority of…
Novo Nordisk (NYSE:NVO)’s takeover of three production sites through the acquisition of Catalent Inc (NYSE:CTLT) is a sensible move, analysts…
Novo Nordisk (NYSE:NVO)’s takeover of three production sites through the acquisition of Catalent Inc (NYSE:CTLT) is a sensible move, analysts…
Catalent downgraded post Novo Nordisk acquisition deal…
Major gummy market participants include Nestle SA, Bayer AG, Church & Dwight Co. Inc, Procter & Gamble, Unilever PLC (OLLY),…
Catalent (CTLT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate…
Catalent acquisition by Novo Nordisk ‘a positive’ - JPMorgan…
BALA CYNWYD, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.…
What could have been a quick profit from an options trade placed late Friday before Novo Holdings A/S said it…
We are investigating the fairness of the sale of Catalent to Novo Holdings for $63.50 per share in cash.…
Catalent is the main supplier of fill-finish work, which involves filling and packaging syringes and injection pens, for Novo Nordisks…
Shares in drug manufacturer Catalent Inc (NYSE:CTLT) soared over 11% in pre-market trading as news broke that Novo Nordisk (NYSE:NVO)’s…
…
The controlling shareholder of weight-loss drug maker Novo Nordisk on Monday said it’s buying a provider of drug manufacturing for…
Novo Holdings acquires Catalent for $16.5 billion…
Novo Holdings to buy Catalent for $11.5 billion to expand Wegovy capacity…
Novo Holdings to buy Catalent for $16.5 billion…
Bagsværd, Denmark, 5 February 2024 – Novo Nordisk today announced that the company has agreed to acquire three fill-finish sites…
Novo Nordisk (NVO) will acquire Catalents three manufacturing sites from Novo Holdings to expand its manufacturing capacity.…
Catalents Indiana plant is filling Wegovy pens to Novo Nordisk for U.S. - ceo…
Catalent, Papa Johns rise on bullish management comments…
Catalents (CTLT) products and services portfolio and technology foundation raise optimism about the stock.…
Companies covered in this study are Abbott, Cardinal Health, Johnson & Johnson, Medtronic, 3M, Steris, Catalent Inc., Smiths Medical Inc.,…
Catalent (CTLT) expects the demand for its pre-filled syringes to improve going forward. The company anticipates the majority of its…
Catalent (CTLT) records lower revenues in Biologics segments in its first-quarter fiscal 2024, resulting in overall soft preliminary performance.…
…
…
Catalent shares added more than 11% after the contract drugmaker’s preliminary first quarter earnings topped expectations and it reaffirmed its full-year...…
Catalent delays quarterly filing with SEC on $700 million impairment charge…
Catalents (CTLT) fiscal Q1 results are likely to be affected by soft performance by the Biologics segment.…
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and…